Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06128629 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 126 to 132
    • Eligibility criteria expanded, about 2 words
    v32
  2. Enrollment target: 765 to 1200
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 132 to 126
    • Study description revised
    v31
  3. Study sites: 127 to 132v30
  4. Study sites: 111 to 127v29
  5. Study sites: 104 to 111v28
Show 26 earlier versionsHide 26 earlier versions
  1. Study sites: 92 to 104v27
  2. Study sites: 84 to 92v26
  3. Study sites: 71 to 84
    • Eligibility criteria shortened, about 7 words
    v25
  4. Study sites: 60 to 71v24
  5. Study sites: 57 to 60v23
  6. Study sites: 51 to 57v22
  7. Study sites: 48 to 51v21
  8. Study sites: 39 to 48v20
  9. Study sites: 36 to 39v19
  10. Study sites: 31 to 36v18
  11. Study sites: 29 to 31v17
  12. Study sites: 26 to 29v16
  13. Study sites: 25 to 26v15
  14. Study sites: 22 to 25v14
  15. Study sites: 21 to 22v13
  16. Study sites: 19 to 21v12
  17. Study sites: 12 to 19v11
  18. Study sites: 9 to 12v10
  19. Study sites: 8 to 9v9
  20. Study sites: 5 to 8v8
  21. Study sites: 4 to 5v7
  22. Study sites: 3 to 4v6
  23. Study sites: 2 to 3v5
  24. Study sites revised (2)v4
  25. Study sites: 1 to 2
    • Start date changed from estimate of Dec 2023 to Dec 13, 2023
    v3
  26. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Trial Details
NCT Number NCT06128629
Lead Sponsor Intellia Therapeutics
Collaborators: Regeneron Pharmaceuticals
Conditions
(from sponsor)		 Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Related terms Amyloidosis, Amyloidosis, Familial, Amyloidosis, Hereditary, Transthyretin-Related, Cardiomyopathies
Enrollment 1,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov